GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

Clinical and Translational Oncology

Volumn 15, Issue 7, 2013, Pages 509-525

  Gonzalez Martin A ^a   Redondo, A ^b   Jurado, M ^c   De Juan, A ^d   Romero, I ^e   Bover, I ^f   Del Campo, J M ^g   Cervantes, A ^h   Garcia Y ⁱ   Lopez Guerrero J A ^e   Mendiola, C ^j   Palacios, J ^k   Rubio, M J ^l   Poveda Velasco, A ^e  

^a MD ANDERSON CANCER CENTER   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^f HOSPITAL SON LLÀTZER   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ HOSPITAL DE SABADELL   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

Chemotherapy; First line; Ovarian cancer; Recurrent disease; Surgery; Treatment guidelines

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; TOPOTECAN; TRABECTEDIN;

ADVANCED CANCER; ALOPECIA; ANAPHYLACTIC SHOCK; ARTERY THROMBOSIS; ARTICLE; BILATERAL CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEARING IMPAIRMENT; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYSTERECTOMY; INFECTION; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAINTENANCE CHEMOTHERAPY; METABOLIC DISORDER; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTECTOMY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEINURIA; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE; VEIN THROMBOSIS; WOUND DEHISCENCE;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; FEMALE; GUIDELINES AS TOPIC; HUMANS; OVARIAN NEOPLASMS; SPAIN;

EID: 84879796193     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0995-8     Document Type: Article

References (99)

1. Poveda Velasco A, Casado Herráez A, Cervantes Ruipérez A, Gallardo Rincón D, García García E, González Martín A, GEICO Group et al (2007) Treatment guidelines in ovarian cancer. Clin Transl Oncol 9(5):308-316
2. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750-755
3. Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM (2010) Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis 51(10):1147-1156
4. American College of Obstetricians and Gynecologists (2007) ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 110(1):201-214
5. Guerriero S, Alcazar JL, Ajossa S, Galvan R, Laparte C, García-Manero M et al (2010) Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer 20(5):781-786
6. Gentry-Maharaj A, Menon U (2012) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 26(2):243-256
7. Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F et al (2012) Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 48(11):1649-1656
8. Bharwani N, Reznek RH, Rockall AG (2011) Ovarian Cancer Management: the role of imaging and diagnostic challenges. Eur J Radiol 78(1):41-51
9. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V et al (2008) Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 199(6):642.e1-642.e6
10. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327-340
11. Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM et al (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109(9):1887-1896
12. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, PLCO Project Team et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22):2295-2303
13. Rosenthal A, Jacobs I (2006) Familial ovarian cancer screening. Best Pract Res Clin Obstet Gynaecol 20(2):321-338
14. Boyd J (2003) Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 88(1 pt 2): S8-S10 (discussion S1-S3)
15. Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, Kibler T et al (2009) Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res 37(Database issue):D820-D823
16. Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 124(2):347-353
17. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307(4):382-390
18. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 30(8):155
19. Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME et al (2009) American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 27(6):986-993
20. Vasen HFA, Watson P, Mecklin J-P, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 116:1453-1456
21. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J et al (2004) Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268
22. Robson ME, Storm CD, Weitzel J, Wollins DS, American Society of Clinical Oncology (2010) American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893-901
23. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34:1407-1416
24. Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I et al (2010) Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol 118(3):299-302
25. Lin KM, Shashidharan M, Thorson AG, Ternent CA, Blatchford GJ, Christensen MA et al (1998) Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 2(1):67-71
26. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967-975
27. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80-87
28. Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC et al (2010) The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116(22):5261-5271
29. Kurman RJ, Shih I (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433-443
30. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41-44
31. Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518
32. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218-224
33. Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol 23(Suppl 10):x111-x117
34. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma.The Cancer Genome Atlas Research Network. Nature 474:609-615
35. Young RH, Gilks CB, Scully RE (1991) Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 15:415-429
36. Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 86:116-119
37. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052-7056
38. Merritt MA, Cramer DW (2011) Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark 9:287-305
39. Kim KR, Choi J, Hwang JE, Baik YA, Shim JY, Kim YM et al (2010) Endocervical-like (Mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology 57:587-596
40. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532-1543
41. Wheeler DT (2004) Borderline ovarian tumors: a web-based atlas. Adv Anat Pathol 11:322
42. Goff BA, Matthews BJ, Larson EH, Andrilla CH, Wynn M, Lishner DM et al (2007) Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109(10):2031-2042
43. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M et al (2010) Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 102(13):982-987
44. Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou T, Sonoda Y (2004) Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 94(3):624-629
45. Ng JS, Low JJ, Ilancheran A (2012) Fertility preservation in gynaecological cancer: epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 26(3):337-345
46. Morice P, Denschlag D, Rodolakis A, Reed N, Schneider A, Kesic V et al (2011) Fertility Task Force of the European Society of Gynecologic Oncology. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer 21(5):951-963
47. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C et al (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103(3):1083-1090
48. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6):1234-1244
49. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R (2011) Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev (8):CD007565. doi: 10.1002/14651858.CD007565.pub2
50. Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12):1202-1210
51. Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21(2):75-80
52. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM et al (2012) An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124(1):10-14
53. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Gynecologic Oncology Group et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34-43
54. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N et al (2003) International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95:105-112
55. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM et al (2003) International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95:125-132
56. (1998) ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators International Collaborative Ovarian Neoplasm Study. Lancet 352:1571-1576
57. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY et al (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102:432-439
58. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95(2):113-125
59. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021-1027
60. Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, Johnson L et al (2011) Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer 105(9):1260-1266
61. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA et al (2000) [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil 28:576-583
62. Ozols RF (2000) Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 10:33-37
63. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W et al (2011) First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 21:756-762
64. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al (1996) Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23:40-47
65. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699-708
66. Adams M, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM et al (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. Br J Cancer 78:1404-1406
67. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
68. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329
69. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C et al (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092
70. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29:3628-3635
71. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S et al (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24:1127-1135
72. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425
73. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G et al (2010) Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 28:4162-4169
74. Hoskins PJ (2009) Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy. J Clin Oncol 27:1355-1358
75. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U et al (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036-1045
76. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT et al (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24:571-578
77. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465
78. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A et al (2009) Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 27:4642-4648
79. Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070-1076
80. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953
81. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338
82. Katsumata N, Yasuda M, Isonishi S, Michimae H, Kimura E, Aoki D et al (2012) Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol 30 (Suppl; abstr 5003)
83. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950-1955
84. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19(4):1001-1007
85. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
86. Jaaback K, Johnson N, Lawrie TA (2011) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 11:CD005340. doi: 10.1002/14651858.CD005340.pub3
87. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496
88. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483
89. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155-1163
90. Lauraine EP, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al (2012) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30 (suppl; abstr LBA5002)
91. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
92. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16:749-755
93. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707
94. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323-3329
95. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045
96. Monk BJ, Herzog TJ, Kaye S, Krasner CN, Vermorken JB, Muggia FM et al (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114
97. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S et al (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22(1):39-48
98. Colombo N (2011) Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study. Int J Gynecol Cancer 21(Suppl 1):S12-S16
99. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95